Hardik Sheth Prashant Kumar Aditya Shreenivas Janani Sambath Ramya Pragya Chetan Madre Nevitha Athikari Hemant Khandare Vishal Peshattiwar Rajan Datar Sewanti Limaye
10.1200/PO.20.00436
JCO Precis Oncol
2021 May 3;5:PO.20.00436.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/34036229/
Anilides / therapeutic use Antineoplastic Agents / therapeutic use Nitriles / therapeutic use Salivary Ducts Salivary Gland Neoplasms / drug therapy Thiazoles / therapeutic use Tosyl Compounds / therapeutic use
Anilides / therapeutic use Antineoplastic Agents / therapeutic use Nitriles / therapeutic use Salivary Ducts Salivary Gland Neoplasms / drug therapy Thiazoles / therapeutic use Tosyl Compounds / therapeutic use Case Reports Class I Phosphatidylinositol 3-Kinases / genetics Humans Male Middle Aged Mutation Neoplasm Staging Receptors, Androgen / biosynthesis Salivary Gland Neoplasms / genetics Salivary Gland Neoplasms / metabolism Salivary Gland Neoplasms / pathology Anilides Antineoplastic Agents Nitriles Receptors, Androgen Thiazoles Tosyl Compounds Alpelisib bicalutamide Class I Phosphatidylinositol 3-Kinases PIK3CA protein, human
PMC8140801
34036229
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report
2021